Patients with non-valvular atrial fibrillation (NVAF) and heart failure with reduced ejection fraction (HFrEF) have significantly lower anticoagulation rates when compared to their HFrEF counterparts, a recent study found. Researchers analyzed the outpatient NCDR PINNACLE-AF registry to identify patients with NVAF and congestive heart failure (CHF). The study population was subdivided into heart failure with preserved ejection fraction (HFpEF) and HFrEF. Anticoagulation rates by CHF group were compared and stratified by CHA2DS2-VASc score. They found:
- 340,127 patients with NVAF and CHF were identified, of whom 248,136 (73.0%) were classified as HFpEF and 91,991 (27.0%) as HFrEF.
- Patients with HFpEF had higher mean CHA2DS2-VASc scores and were more likely to be female, older, and have hypertension.
- Unadjusted anticoagulation rates were significantly lower in patients with HFpEF vs those with HFrEF.
Contreras JP, Hong KN, Castillo J, et al. Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF Registry. [Published online ahead of print December 23, 2018]. Clin Cardiol. doi:10.1002/clc.23142.
Must Reads in Arrhythmias & EP
Impact of HF Type on Bleeding Risk in Patients with AF, Am J Cardiol; ePub 2019 Feb 28; Mentias, et al
Frailty & Cognitive Impairment in AF, Am Heart J; ePub 2019 Jan 30; Madhavan, et al
Adherence to Stroke Prevention Therapy for AF, Circulation; ePub 2019 Jan 31; Piccini, et al
Sudden Cardiac Death Risk in the US, Am J Cardiol; ePub 2019 Jan 24; Olson, et al